Information Provided By: 
Fly News Breaks for March 1, 2019
RVNC
Mar 1, 2019 | 09:32 EDT
SunTrust analyst Ashwani Verma lowered his price target on Revance to $29 after its wider than expected Q4 loss, saying the lower cost alternatives to Botox "changes the market reality" for the company. The analyst believes that there are few catalysts for Revance this year, but sees 2020 as rich with potentially positive news flow with expected regulatory approval for its glabellar lines product and the results of the phase 2 study of its Plantar Fasciitis / Upper Limb Spasticity program. Verma is keeping his Buy rating on Revance.
News For RVNC From the Last 2 Days
There are no results for your query RVNC
